Amgen and Molecular Partners Team Up in Immuno-Oncology Deal; Rights Returned

27 Apr 2022

Molecular Partners AG licensed Amgen Inc. exclusive worldwide rights to develop and commercialize its cancer candidate MP0310.

Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)

Already a Biomedtracker subscriber? You have access to the full deal record through your subscription

Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.

Questions?

Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com

Related Companies

Amgen and Molecular Partners Team Up in Immuno-Oncology Deal; Rights Returned

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

DCD.EmailPopout.Notice